About the Authors

Mario Nuvolone

mario.nuvolone@unipv.it (MN); adriano.aguzzi@usz.ch (AA)

Affiliations Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland, Amyloidosis Research and Treatment Center, Foundation Scientific Institute Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Pavia, Italy

Marta Paolucci

Affiliation Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland

Silvia Sorce

Affiliation Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland

Veronika Kana

Affiliation Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland

Rita Moos

Affiliation Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland

Takashi Matozaki

Affiliation Division of Molecular and Cellular Signaling, Department of Biochemistry and Molecular Biology, Kobe University Graduate School of Medicine, Kobe, Japan

Adriano Aguzzi

mario.nuvolone@unipv.it (MN); adriano.aguzzi@usz.ch (AA)

Affiliation Institute of Neuropathology, University Hospital of Zurich, Zurich, Switzerland

Competing Interests

Adriano Aguzzi is a founder, director, and shareholder of Mabylon, a company dedicated to the discovery of human disease-related antibodies. He does not receive any salary from Mabylon who did not have any role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Author Contributions

Conceptualization: MN VK AA. Data curation: MN MP. Formal analysis: MN MP AA. Funding acquisition: AA. Investigation: MN MP SS RM. Methodology: MN SS TM AA. Project administration: MN AA. Resources: TM AA. Supervision: AA. Validation: MN AA. Visualization: MN MP. Writing – original draft: MN MP AA. Writing – review & editing: SS VK RM TM.